Schedule 13G ownership disclosure

ADC THERAPEUTICS SA

Common Shares, par value CHF $0.08 per share · CUSIP: H0036K147

Event date: 2025-10-27

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • TCG Crossover GP II, LLC

    Shares: 11,390,175 · Class: 9.2%

  • TCG Crossover Fund II, L.P.

    Shares: 11,390,175 · Class: 9.2%

  • Chen Yu

    Shares: 11,390,175 · Class: 9.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-054764
Form type
SCHEDULE 13G
Filer
ADC Therapeutics SA
CIK
CIK 1771910
Filed
Feb 17, 2026
Reporting period
Oct 27, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub